IBD-Associated Arthritis

Top Story

Biosimilars unlikely to save costs as expected, experts say

May 4, 2017

Despite being heralded as lower-cost alternatives to branded biologics, the approval of biosimilar therapies for chronic diseases is not likely to yield expected cost savings due to a number of state and payer policies, according to an opinion piece published in JAMA.

However, cost-savings may be attainable after key challenges to biosimilar substitution are overcome, the authors concluded.

Meeting NewsVideo

VIDEO: Speaker reviews factors that impact response to treatment for Crohn’s disease, ulcerative colitis

March 28, 2017
NEW YORK — At the Interdisciplinary Autoimmune Summit, Steven B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern University, Feinberg…
Curbside Consultation

Biologic Therapies for Inflammatory Bowel Disease

Healio Rheumatology, March 2017
Maria Laura Annunziata, MD, PhD; David T. Rubin, MD
A: Current biologic therapies for inflammatory bowel disease include infliximab and adalimumab, which were approved in North America, Australia and Western Europe…
By the Book

Immunomodulators Azathioprine/6-Mercaptopurine and Methotrexate

Healio Rheumatology, February 2017
David T Rubin, MD; Miles P Sparrow, MBBS, FRACP
Treatment aims in the inflammatory bowel diseases are evolving beyond the induction and maintenance of corticosteroid-free remission. More recently, it has become…
In the Journals

Biosimilars unlikely to save costs as expected, experts say

May 4, 2017
Despite being heralded as lower-cost alternatives to branded biologics, the approval of biosimilar therapies for chronic diseases is not likely to…

Meeting NewsVideo

VIDEO: Speaker reviews factors that impact response to treatment for Crohn’s disease, ulcerative colitis

March 28, 2017
NEW YORK — At the Interdisciplinary Autoimmune Summit, Steven B. Hanauer, MD, medical director of the Digestive Health Center

Curbside Consultation

Biologic Therapies for Inflammatory Bowel Disease

Healio Rheumatology, March 2017
Maria Laura Annunziata, MD, PhD; David T. Rubin, MD
A: Current biologic therapies for inflammatory bowel disease include infliximab and adalimumab, which were approved in North America, Australia and…

By the Book

Immunomodulators Azathioprine/6-Mercaptopurine and Methotrexate

Healio Rheumatology, February 2017
David T Rubin, MD; Miles P Sparrow, MBBS, FRACP
Treatment aims in the inflammatory bowel diseases are evolving beyond the induction and maintenance of corticosteroid-free remission. More recently…

FDA NewsPerspective

FDA issues draft guidance on biosimilar interchangeability

January 18, 2017
The FDA has released a draft guidance for industry outlining criteria for demonstrating that a biosimilar is interchangeable with a reference product…

By the Numbers

8 IBD updates from ACG, UEG Week

November 1, 2016
Several developments in inflammatory bowel disease were presented at the two major gastroenterology conferences last month: the American College of…

Meeting NewsPerspective

NOR-SWITCH: Switching to Remicade biosimilar safe, noninferior

October 24, 2016
Switching to biosimilar Remicade was safe and noninferior to continued treatment with the originator product across multiple indications, including…

Editorial

The Rising Tide of Autoimmunity: Highlights of the International Autoimmunity Summit

Healio Rheumatology, May 2016
Leonard H. Calabrese, DO
The International Autoimmunity Summit gathered several hundred experts who span the spectrum of autoimmune diseases, which are often referred to as…

By the Book

Extraintestinal Manifestations of IBD

Healio Rheumatology, April 2016
Ellen J. Scherl, MD
Extraintestinal manifestations of inflammatory bowel disease occur frequently. Disorders involving practically all organ systems have been reported…

New industry body launched to promote biosimilars in the UK

April 19, 2016
A new industry body, the British Biosimilars Association, has been launched to promote the use of biosimilar drug treatments in the United Kingdom…

More Headlines »
Advertisement
Advertisement